<DOC>
	<DOC>NCT01841567</DOC>
	<brief_summary>The overall rationale for this study is to evaluate the clinical performance potential for Mepilex Border Post-Op in the ability to minimise the risk of blistering, maceration and less dressing change due to high absorption capacity. This study is a part of Post Market Clinical Follow-Up (PMCF).</brief_summary>
	<brief_title>Post Market Clinical Follow-up Study</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1. Age 45 years 2. Have an expected total length of stay of 4 or more days 3. Undergoing elective primary arthroplasty of the hip or knee 4. Undergoing hip surgery with a standard access 5. Give their written informed consent to participate Exclusion Criteria 1. Dressing size does not fit the incision area 2. Known allergy hypersensitivity to any of the components of the dressing 3. Multitrauma 4. Undergoing arthroplasty due to tumour 5. Fractures 6. Wound at the surgical site prior to surgery 7. Neurological deficit of operated side 8. Subject has documented skin disease at time of enrolment, as judged by the investigator 9. Previously enrolled in the present investigation 10. Subject included in other ongoing investigation at present, as judged by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>hip</keyword>
	<keyword>knee</keyword>
</DOC>